When looking at our recent coverage on Femtech Insider one could argue that the women's health industry is experiencing a bit of a transformation these days with the integration of GLP-1 agonists into various health platforms and services.
Originally developed for diabetes management, the drugs have recently since gained prominence for their efficacy in weight loss, with potential benefits also extending to cardiovascular health, fertility and beyond.
As companies across the femtech spectrum—from sexual wellness brands to menopause-focused platforms—incorporate GLP-1s into their offerings, I think it's crucial to have a closer look at the implications, challenges, and also the potential consequences of this trend.
But let's start from the beginning...
The Rise of GLP-1s: From Diabetes Treatment to Weight Loss Phenomenon
The GLP-1 story actually began in the diabetes treatment space. Drugs like semaglutide (aka Ozempic) were initially approved for managing Type 2 diabetes. However, a significant side effect—weight loss—caught the attention of both patients and healthcare providers. This led to the development and approval of higher-dose versions specifically for weight management, such as Wegovy (semaglutide) and Saxenda (liraglutide).
The effectiveness of these drugs in promoting weight loss, coupled with celebrity endorsements and social media buzz, created unprecedented demand.
By 2022, this surge in popularity led to widespread shortages of both the diabetes and weight loss formulations. The scarcity of FDA-approved GLP-1 agonists created a complex landscape:
- Manufacturers struggled to keep up with demand due to production capacity limitations and raw material shortages
- The shortage of weight loss-specific formulations led to increased off-label prescribing of diabetes medications for weight management.
- The shortages opened the door for compounding pharmacies to create their versions of GLP-1 agonists, operating in a regulatory gray area.
- The combination of high demand and limited supply fueled the rise of telehealth platforms offering easier access to these medications, often through compounded versions (Think Ro/Rory & Hims/Hers)
It is this market dynamic that has played a crucial role in shaping the current landscape of GLP-1 use in women's health, setting the stage for both innovation and a bit of controversy.
The Science and Market Dynamics
GLP-1 agonists work by mimicking a hormone that targets areas of the brain involved in appetite regulation and food intake. Studies report that more than half of patients lose 20% or more of their body weight. Beyond weight loss, these drugs have shown promise in reducing cardiovascular risks and improving fertility.
The rapid adoption of GLP-1s in women's health reflects a growing demand for effective weight management solutions. However, this trend also raises questions about the drivers behind this shift.
Is it primarily motivated by medical need or are market forces playing a significant role? And does the rush to embrace these drugs risks promoting a 'quick fix' mentality that could potentially undermine more comprehensive, lifestyle-based approaches to health?
Critical Concerns: Side Effects and Long-Term Impacts
While the weight loss efficacy of GLP-1s is well-documented, their long-term effects and appropriateness for broader populations remain areas of concern.
Common side effects include gastrointestinal issues, which can significantly impact quality of life and medication adherence. Another concern are the potential long-term effects on muscle mass and bone density, particularly in older women already at risk of osteoporosis (more on this in a bit).
The psychological effects of GLP-1s also warrant careful consideration: Rapid weight loss can add to existing body image issues or disordered eating patterns, a concern that women's health platforms must address head-on. Moreover, the impact of these drugs on mood and potential interplay with depression symptoms adds another layer of complexity to their use in women's health.
GLP-1s, Menopause & Bone Density
The use of GLP-1s during menopause shows the nuanced challenges in women's health. While these drugs offer potential benefits for weight management during this transition, their impact on bone density is a concern.
Menopause comes with significant hormonal changes that often lead to increased abdominal fat, changes in body composition, and an elevated risk of osteoporosis due to declining estrogen levels (among other symptoms).
The potential benefits of GLP-1s in menopausal women include weight loss, which can reduce stress on bones and joints, and improved metabolic health. But these benefits are counterbalanced by critical concerns: Rapid weight loss can accelerate bone loss - a process already problematic during menopause.
These clinical implications call for a careful risk-benefit analysis. An individualized approach based on baseline bone density, fracture risk, and overall health status is crucial.
The Accessibility Issue
Given this need to careful consideration, one thing I have found particularly notable is the surprising ease with which these medications can be obtained, even by individuals who may not have a clear medical need for them.
According to a recent investigation by Wired many telehealth platforms offer minimal vetting, often relying on self-reported information without verification. This ease of access raises significant ethical and safety concerns, including the potential for misuse and the lack of proper medical oversight.
And the simplicity of obtaining GLP-1 drugs through these channels could lead to several adverse outcomes, including overuse, and strain on supply for patients with genuine medical needs.
Needless to say: This is very concerning, and I hope platforms will take genuine steps to address these issues.
What's Next?
As the GLP-1 trend evolves in the women's health space, several key areas (beyond the access issue mentinoned above) will need attention:
- Research Priorities: There is a critical need for women-specific studies examining the effects of GLP-1s across different life stages. Long-term data, especially regarding cardiovascular, bone, and reproductive health, is essential.
- Integrated Care Models: The future of GLP-1 use in women's health lies in the development of comprehensive care models that go beyond medication. These models should integrate nutritional counseling, exercise programs, mental health support, and regular monitoring of various health markers
- Ethical Framework Development: The women's health industry must grapple with the ethical implications of promoting weight loss drugs in a society already struggling with body image issues. Developing a robust ethical framework that balances health promotion with body positivity will be crucial. (Sidenote: Hims/Hers spent $145M in one single quarter marketing its weight loss offering. What. a. number.)
- Technological Integration: The future may also see the integration of GLP-1 treatments with digital health technologies, enabling more precise monitoring and personalization.
So...
I think that the "GLP-1 revolution" in women's health is without a doubt already underway, but it is also without a doubt a bit of a double-edged sword, offering unprecedented efficacy in weight management while also raising some ethical and medical questions.
The challenge lies not just in leveraging the benefits of these drugs, but in reshaping our approach to women's health holistically. The true measure of success will be whether we can leverage GLP-1s to catalyze a broader transformation in how we understand, treat, and support women's health across all life stages.
The path forward demands not only more research and potentially more regulation, but also a fundamental reevaluation of our societal attitudes towards weight, health, and the role of medication in achieving wellness.
As always: There's lots to be done.
